|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
Swiss drugmaker Roche upped its bet on personalised cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations from solid tumours from a patient's blood. The blood test, called FoundationOne Liquid, is among initial products to emerge from Foundation Medicine after Roche spent $2.4 billion on the U.S.-based genetic profiling company this year on the conviction that future cancer treatment will be tailored to individual characteristics of a patient's tumour.
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Foundation Medicine, today announced the publication of the results of a large study demonstrating that its novel, investigational assay to measure blood tumor mutational burden (bTMB) can help predict response to the anti-PD-L1 immunotherapy, atezolizumab, (TECENTRIQ®) in patients with previously treated non-small cell lung cancer (NSCLC). The study, published in the journal Nature Medicine, was the result of a collaboration between Foundation Medicine and Genentech, a member of the Roche Group, and demonstrates the potential of bTMB to expand precision oncology approaches for patients with advanced cancers, including metastatic lung cancer. In addition, these results show that bTMB may be an independent predictor of clinical benefit, regardless of PD-L1 expression as assessed by immunohistochemistry.
OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced that Roche`s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Foundation Medicine not already owned by Roche or its affiliates, at a price of $137.00 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 30 July 2018 and was not extended.
LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on TROV sign up now at www.wallstequities.com/registration. WallStEquities.com draws investors' attention to the Medical Laboratories and Research category, which includes companies that focus on performing various tests on patients that give them information on patients' health. Lined up for review are the following equities: Foundation Medicine Inc. (NASDAQ: FMI), NeoGenomics Inc. (NASDAQ: NEO), Neuronetics Inc. (NASDAQ: STIM), and TrovaGene Inc. (NASDAQ: TROV).